ESC 365 - Mavacamten in a real-world hypertrophic cardiomyopathy population: how many may be eligible?

ESC2024 Premium Access

Mavacamten in a real-world hypertrophic cardiomyopathy population: how many may be eligible?

Session: Cardiac myosin inhibitors for treatment of hypertrophic obstructive cardiomyopathy

Topic: Hypertrophic Cardiomyopathy

Speaker: Doctor M. Lima (Lisbon, PT)

Event: ESC Congress 2024

Congress Presentation

About the speaker

Doctor Maria Rita Lima

Hospital Santa Cruz, Lisbon (Portugal)

1 follower

3 more presentations in this session

Serial changes in left and right ventricular global longitudinal strain in symptomatic obstructive hypertrophic cardiomyopathy treated with mavacamten: insights from VALOR-HCM trial

Speaker: Doctor M. Desai (Cleveland, US)

Exploring the effects of mavacamten through hemodynamic force analysis in patients with obstructive hypertrophic cardiomyopathy

Speaker: Doctor A. Milazzo (Florence, IT)

A comprehensive evaluation of available evidence of mavacamten in obstructive HCM: a meta-analysis of randomised controlled trials.

Speaker: Doctor A. Elmorsy (Tanta, EG)

Access the full session

Cardiac myosin inhibitors for treatment of hypertrophic obstructive cardiomyopathy

Speakers: Doctor M. Lima, Doctor M. Desai, Doctor A. Milazzo, Doctor A. Elmorsy

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources